Arca
Skip to content
Tools
Tools

IGHE: Immunoglobulin heavy constant epsilon

Constant region of immunoglobulin heavy chains.

  • Drugs that act on it: 6
  • Approved: 1
  • In phases 1 to 3: 5
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on IGHE, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 4
  • Other 2

Approved1

  • Omalizumab

Phase 31

  • Ligelizumab

Phase 23

  • AL-901
  • Quilizumab
  • Talizumab

Phase 11

  • MEDI-4212

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Longbio Pharma117%
  • MedImmune LLC117%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Ig epsilon chain C region inhibitor.
OmalizumabBoxed warningApprovedLongbio PharmaAntibodyInhibitor33
LigelizumabPhase 3Novartis PharmaceuticalsAntibodyInhibitor0
AL-901Phase 2—OtherInhibitor0
QuilizumabPhase 2RocheAntibodyInhibitor0
TalizumabPhase 2—AntibodyInhibitor0
MEDI-4212Phase 1MedImmune LLCOtherInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesOmalizumabPhase 3Not yet recruitingLongbio PharmaNov 18, 2026
Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyOmalizumabPhase 4RecruitingJohns Hopkins UniversitySep 29, 2026
Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.Omalizumab—RecruitingCentre Hospitalier Universitaire de BesanconSep 22, 2026
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDOmalizumab—RecruitingShanghai Pulmonary Hospital, Shanghai, ChinaSep 16, 2026
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksOmalizumabPhase 3RecruitingNovartis PharmaceuticalsSep 11, 2026
Expression of TSLP Isoforms in AsthmaOmalizumab—RecruitingMedical University of WarsawAug 26, 2026
Effects of Diet and Oxidative Stress on Disease Severity and Response to Omalizumab in Chronic Spontaneous UrticariaOmalizumab—Enrolling by invitationIstanbul Training and Research HospitalFeb 24, 2026
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab BiosimilarOmalizumab—RecruitingCelltrion HealthCare FranceFeb 23, 2026

Diseases most associated with it

Open Targets association score, 0 to 1; all associations
  • Chronic idiopathic urticaria0.42
  • Allergic asthma0.42
  • Chronic rhinosinusitis with nasal polyps0.38
  • Airway obstruction0.37
  • Peanut allergic reaction0.37
  • Food allergy0.33
  • Egg allergy0.30
  • Wheat allergic reaction0.30

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1834, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01854, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.